GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrat
GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human m
A malaria vaccine developed by members of the University of Oxford team that created the AstraZeneca COVID-19 jab has been approved in its first market, Ghana.
Moderna’s aspiration to become a player in the seasonal influenza vaccine market has hit a hurdle – likely a delay rather than anything more serious – but its stock has st
A recent Biomedical Research & Bio-Products AG phase 2 study showed that its TSST-1 vaccine is safe and effective against Staphylococcal-induced Toxic Shock Syndrome (
Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be